Collagen Hydrogel Encapsulation to Preserve Islet Viability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current islet transplantation therapies for type 1 diabetes face challenges such as limited donor supply, rapid cell death during in-vitro culture, and the need for chronic immunosuppression, leading to poor engraftment and function of insulin-producing cells.
Innovation Solution
Development of collagen-based compositions that encapsulate insulin-producing cells, allowing for minimally invasive administration and promoting long-term engraftment without systemic immunosuppression, by creating a semi-solid microenvironment that supports cell survival and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional in-vitro culture in suspension is used, then islet isolation and transplantation can be performed, but beta cells undergo rapid cell death and lose glucose-sensitive insulin release function
Solution Approach 1:
The patent uses a collagen-based hydrogel matrix as an intermediary substance to replace conventional suspension culture. This hydrogel provides a three-dimensional microenvironment that mimics the native extracellular matrix, allowing islets to maintain viability and function during in-vitro culture without direct cell-substrate contact requirements. The hydrogel acts as a mediator between the islets and the culture medium, enabling prolonged culture periods while preserving beta cell function.
Solution Approach 2:
The patent changes the physical and chemical parameters of the culture environment by using a collagen hydrogel matrix with specific rheological properties. The hydrogel's viscoelastic characteristics, pore size, and biochemical composition are optimized to support islet survival. This parameter change from suspension to hydrogel-embedded culture transforms the cultural conditions to better match in-vivo islet microenvironment, thereby extending islet viability during culture.
2Ease of manufacture
If transplanted islets are provided without encapsulation, then transplantation procedure is simple, but microenvironmental cues are lost and engraftment fails
Solution Approach 1:
The patent applies preliminary action by pre-encapsulating islets in a collagen hydrogel matrix before transplantation. This pre-prepared microenvironment provides structural support and biochemical cues that are essential for islet engraftment. The hydrogel is formulated and prepared in advance with appropriate mechanical properties and biochemical signals, so that when islets are transplanted, they immediately have access to the necessary microenvironmental cues for survival and function, eliminating the need for complex post-transplantation support structures.
3Reliability
If chronic immunosuppression is used, then transplanted islets can survive, but patient defense mechanisms are compromised with significant risks and side effects
Solution Approach 1:
The patent applies self-service by designing a collagen hydrogel matrix that inherently protects transplanted islets from immune rejection without requiring systemic immunosuppression. The hydrogel's biochemical composition and physical structure create a protective microenvironment that modulates local immune responses, allowing islets to survive and function in immunocompetent hosts. This self-protective mechanism eliminates the need for external immunosuppressive drugs and their associated side effects.
4Productivity
If islets are transplanted without preservation strategy, then rapid use is required, but this limits treatment options and requires complex logistics
Solution Approach 1:
The patent enables continuity of useful action by allowing islets to be maintained in a viable, functional state during in-vitro culture in collagen hydrogel for extended periods. This continuous preservation capability means islets can be cultured, prepared, and transported without losing function, providing a continuous supply of viable islets for transplantation. This eliminates the urgency for immediate use and allows for better surgical scheduling and patient preparation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen encapsulation maintains islet viability and function in vitro for over 14 days and in vivo for over 90 days, achieving normoglycemia and reducing the need for chronic immunosuppression, thereby improving the quality of life and health status for patients with type 1 diabetes.
Implementation Method 1
combining an acidic collagen oligomer solution with a self-assembly reagent to make a combined solution; adding islets to the combined solution to make a suspension, thereby forming a semisolid collagen-islet composition
Data Source
AI summary
Compositions comprising collagen and insulin-producing cells are provided. Processes for making such a collagen and insulin-producing cell compositions are also provided. Methods for controlling, or lowering blood glucose levels and treating metabolic disorders in mammals, including type 1 diabetes, with such compositions are further provided. Methods to prolong insulin-producing cell viability and function in vitro or during transport are also provided.